← Volver a la portada
Oceanía · Agencias y tiempo real · AAP

AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site

Publicado por AAP · Australia hace 11 h

Resumen detallado

Among the projects the Yokohama site will support is a research program led by the Institute of Science Tokyo aimed at advancing third-party virus-specific T cell therapy for…

Developers ranging from academic institutions to biotechnology companies select AGC Biologics for its proven commercial track record

Showcases momentum for Japan’s cell and gene therapy ecosystem following proactive government initiatives

YOKOHAMA, Japan, Nov. 16, 2026 (GLOBE NEWSWIRE) -- While there is growing interest and momentum for cell and gene therapy development in Japan, there are a limited number of CDMOs with the institutional knowledge, manufacturing prowess, talent development, and international network. To advance their projects in a fast-paced, resource-constrained environment, three biopharma developers including the Institute of Science Tokyo have selected AGC Biologics to provide cell therapy services from its new Yokohama location.

AGC established its cell therapy services in Yokohama in July 2025, bringing together two strong legacies: thirty years of expertise and the track record of the AGC Biologics Milan site, and AGC Group’s century-plus manufacturing excellence in Japan. Combined, those legacies position AGC to meet the burgeoning needs of the cell and gene therapy industry.

As part of these new projects, the AGC Biologics Yokohama site will provide services such as process transfer and manufacturing services for pre-clinical and clinical trials. Core technologies available for developers with diverse needs include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, exosomes, and CAR-T cell therapies.

Supporting Clinical Translation of Virus-Specific T Cell Therapy Research

Among the projects the Yokohama site will support is a research program led by the Institute of Science Tokyo aimed at advancing third-party virus-specific T cell therapy for treatment-resistant adenovirus infections following hematopoietic cell transplantation toward clinical application.

“Viral infections following hematopoietic cell transplantation represent a major clinical challenge in patients with compromised immune function and can lead to…

Inicio del artículo, extracto de AAP. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en AAP Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.aap.com.au)